CD8A and neoplasm: To evaluate the clinical significance of our classification, we compared the characteristics of tumor immune microenvironment between the two groups of PTMC-TCGA patients and discovered that patients with inflammatory signature had higher immune scores (Fig. 6d), more CD8 + T cells (Fig. 6e), and higher expression of immune checkpoint proteins (Fig. 6f), indicating that the prediction model may classify patients with different immunity.